Ekso Bionics Holdings, Inc.
EKSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | 6.62 | -0.34 | 0.78 |
| FCF Yield | -5.36% | -2.35% | -6.43% | -2.31% |
| EV / EBITDA | -19.46 | -39.29 | -15.56 | -49.12 |
| Quality | ||||
| ROIC | -50.31% | -67.42% | -45.28% | -32.33% |
| Gross Margin | 53.06% | 49.67% | 48.13% | 60.01% |
| Cash Conversion Ratio | 0.87 | 0.79 | 0.97 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.55% | 17.58% | 13.28% | -6.86% |
| Free Cash Flow Growth | 19.06% | 17.95% | -32.70% | -28.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.11 | 0.93 | 4.20 |
| Interest Coverage | -38.88 | -50.04 | -99.72 | -122.37 |
| Efficiency | ||||
| Inventory Turnover | 1.84 | 1.82 | 1.29 | 2.01 |
| Cash Conversion Cycle | 278.35 | 239.80 | 241.69 | 81.10 |